India just put a ₹10,000 crore bet on becoming the world's biologics factory.
The government has rolled out the Biopharma SHAKTI scheme — a five-year push to build India's own biologics, biosimilars, and clinical trial muscle, so the country stops importing what it could be making at home.
Six listed pharma names are already being watched closely because of it.
Here's the part that should worry the rest of the world's drugmakers.
India already does generics at scale.
Cheap. Fast. Everywhere.
Now it wants biologics — the harder, pricier, patent-protected stuff — too.
This isn't just a subsidy cheque. It's infrastructure, top to bottom:
The whole chain — discovery to packaging — gets funded in one shot.
India's biopharma market is worth roughly $8.9 billion today.
It's expected to nearly double to $17.4 billion by 2033.
Right now, India punches below its weight — strong in generics, weak in the biologics and gene-therapy space that commands real pricing power globally.
SHAKTI is the government trying to close that gap before someone else does.
Markets reacted fast. Stocks with biologics or CRDMO exposure are being tagged as early beneficiaries:
None of this guarantees returns.
But it does confirm one thing: the government just told the market where it's placing its chips for the next five years.
That's all for now!
